Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Insight Molecular Diagnostics (IMDX) Operating Expenses: 2020-2025

Historic Operating Expenses for Insight Molecular Diagnostics (IMDX) over the last 6 years, with Sep 2025 value amounting to $11.2 million.

  • Insight Molecular Diagnostics' Operating Expenses fell 17.53% to $11.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $63.7 million, marking a year-over-year increase of 46.09%. This contributed to the annual value of $61.8 million for FY2024, which is 141.81% up from last year.
  • Insight Molecular Diagnostics' Operating Expenses amounted to $11.2 million in Q3 2025, which was up 9.76% from $10.2 million recorded in Q2 2025.
  • In the past 5 years, Insight Molecular Diagnostics' Operating Expenses ranged from a high of $34.2 million in Q4 2024 and a low of -$5.8 million during Q1 2023.
  • Over the past 3 years, Insight Molecular Diagnostics' median Operating Expenses value was $9.3 million (recorded in 2024), while the average stood at $10.6 million.
  • The largest annual percentage gain for Insight Molecular Diagnostics' Operating Expenses in the last 5 years was 416.96% (2023), contrasted with its biggest fall of 162.38% (2023).
  • Insight Molecular Diagnostics' Operating Expenses (Quarterly) stood at $17.8 million in 2021, then crashed by 34.69% to $11.6 million in 2022, then surged by 38.22% to $16.1 million in 2023, then surged by 113.06% to $34.2 million in 2024, then dropped by 17.53% to $11.2 million in 2025.
  • Its last three reported values are $11.2 million in Q3 2025, $10.2 million for Q2 2025, and $8.1 million during Q1 2025.